

W.J. "BILLY" TAUZIN, LOUISIANA
RALPH M. HALL, TEXAS
MICHAEL BILIRAKIS, FLORIDA
FRED UPTON, MICHIGAN
CLIFF STEARNS, FLORIDA
PAUL E. GILLMOR, OHIO
JAMES C. GREENWOOD, PENNSYLVANIA
CHRISTOPHER COX, CALIFORNIA
NATHAN DEAL, GEORGIA
RICHARD BURR, NORTH CAROLINA
ED WHITFIELD, KENTUCKY
CHARLIE NORWOOD, GEORGIA
BARBARA CUBIN, WYOMING
JOHN SHIMKUS, ILLINOIS
HEATHER WILSON, NEW MEXICO
JOHN B. SHADEGG, ARIZONA
CHARLES W. "CHIP" PICKERING, MISSISSIPPI
VITO FOSSELLA, NEW YORK
STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
CHARLES F. BASS, NEW HAMPSHIRE
JOSEPH R. PITTS, PENNSYLVANIA
MARY BONO, CALIFORNIA
GREG WALDEN, OREGON
LEE TERRY, NEBRASKA
MIKE FERGUSON, NEW JERSEY
MIKE ROGERS, MICHIGAN
DARRELL E. ISSA, CALIFORNIA
C.L. "BUTCH" OTTER, IDAHO
JOHN SULLIVAN, OKLAHOMA

ONE HUNDRED EIGHTH CONGRESS

U.S. House of Representatives
Committee on Energy and Commerce
Washington, DC 20515-6115

JOE BARTON, TEXAS
CHAIRMAN

December 9, 2004

JOHN D. DINGELL, MICHIGAN
HENRY A. WAXMAN, CALIFORNIA
EDWARD J. MARKEY, MASSACHUSETTS
RICK BOUCHER, VIRGINIA
EDOLPHUS TOWNS, NEW YORK
FRANK PALLONE, JR., NEW JERSEY
SHERROD BROWN, OHIO
BART GORDON, TENNESSEE
PETER DEUTSCH, FLORIDA
BOBBY L. RUSH, ILLINOIS
ANNA G. ESHOO, CALIFORNIA
BART STUPAK, MICHIGAN
ELIOT L. ENGEL, NEW YORK
ALBERT R. WYNN, MARYLAND
GENE GREEN, TEXAS
KAREN MCCARTHY, MISSOURI
TED STRICKLAND, OHIO
DIANA DEGETTE, COLORADO
LOIS CAPPS, CALIFORNIA
MICHAEL F. DOYLE, PENNSYLVANIA
CHRISTOPHER JOHN, LOUISIANA
TOM ALLEN, MAINE
JIM DAVIS, FLORIDA
JAN SCHAKOWSKY, ILLINOIS
HILDA L. SOLIS, CALIFORNIA
CHARLES A. GONZALEZ, TEXAS

BUD ALBRIGHT, STAFF DIRECTOR

The Honorable Tommy Thompson
Secretary
Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C. 20201

Dear Secretary Thompson:

The Committee on Energy and Commerce is investigating drug safety issues related to Vioxx, as well as broader issues raised at Committee hearings and elsewhere about the adequacy of the Food and Drug Administration (FDA) to address concerns related to the safety of prescription drugs approved by the FDA. At the request of this Committee, the Government Accountability Office (GAO) is examining how the FDA Center for Drug Evaluation and Research (CDER) manages internal disagreements over the handling of drug safety issues.

We note that at your press conference on December 3rd you stated that the Administration will present a plan to reform FDA's regulation of drug safety. Further, you suggested that this initiative could feature the creation of a drug safety entity with greater independence from FDA's review functions.

We write to express our appreciation for your comments and interest in this issue. While the Committee is actively investigating issues that bear directly on FDA's drug safety program, we are eager to work with you on sensible and pro-active reforms you are considering regarding the drug safety program concerns at FDA.

To enhance the credibility of this initiative, we recommend that the drug safety review include interviews with appropriate FDA management officials at CDER as well as FDA scientists who have concerns about the drug safety program. The review, including personnel interviews, should be conducted by staff independent of CDER. We emphasize that the Department take all necessary steps to assure that no negative employment consequences attach to staff that express concern about the FDA's handling of drug safety issues. If the review is already proceeding this way, we would appreciate that assurance from the Department.

The Honorable Tommy Thompson
Page 2


Although you indicated at the press conference that the Administration would present its plan in the next two weeks, we would be supportive of the Administration if it took a few extra weeks to strengthen the quality and enhance the credibility of the review, and presented its findings by January 19, 2005.

We commend you for your willingness to take quick action, but emphasize this drug-safety review be conducted with objectivity, independence, and fairness. Public confidence in the safety of our drug supply as well as the regulatory ability and independence of the FDA is at stake.

Sincerely,



Joe Barton
Chairman



John D. Dingell
Ranking Member